Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00370591
Status:
COMPLETED
Last Update Posted:
2016-09-15
First Post:
2006-08-30
Brief Title:
Study Of Airway Physiology In Adults SERETIDE DISKUS Inhaler and FLIXOTIDE Inhaler Are Trademarks of GSK Croup of Companies
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Randomised Double Blind Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS Inhaler 50100 mcg Twice Daily vs FLIXOTIDE Inhaler 200 mcg Twice Daily
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Comparison of two asthma treatments by lung function measures
Detailed Description:
Single centre randomised double-blind comparator study to demonstrate superiority of salmeterolfluticasone propionate combination product 50100mcg bd over fluticasone propionate 100mcg bd with respect to improvements in airway physiology sRAW in adults with persistent asthma treated for 4 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None